Deal watch: Acceleron and Shire to target the activin receptor pathway for muscular disorders.
D029404:Activin Receptors / Q000378:metabolism; D030301:Activin Receptors, Type II / Q000378:metabolism*; D016503:Drug Delivery Systems / Q000379:methods*; D004345:Drug Industry / Q000379:methods* / Q000639:trends*; D006801:Humans; D009135:Muscular Diseases / Q000188:drug therapy* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology*
D029404:Activin Receptors; D030301:Activin Receptors, Type II; C425584:activin receptor type II-B